Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients
about
Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness lossImpact of the HIV-1 env genetic context outside HR1-HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in clinical isolatesMolecular mechanisms of recombination restriction in the envelope gene of the human immunodeficiency virusRNA structures facilitate recombination-mediated gene swapping in HIV-1Identification of a gp41 core-binding molecule with homologous sequence of human TNNI3K-like protein as a novel human immunodeficiency virus type 1 entry inhibitor.Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures.HIV-1 drug-resistance and drug-dependence.Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtideViral dynamics and in vivo fitness of HIV-1 in the presence and absence of enfuvirtide.Altered bystander apoptosis induction and pathogenesis of enfuvirtide-resistant HIV type 1 Env mutantsEnfuvirtide: from basic investigations to current clinical use.HIV-1 Entry, Inhibitors, and ResistanceEscape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.HIV-1 diversity in the envelope glycoproteins: implications for viral entry inhibition.Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy.Two-way Bayesian hierarchical phylogenetic models: An application to the co-evolution of gp120 and gp41 during and after enfuvirtide treatment.Peptide P5 (residues 628-683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infectionCombinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains.HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide.Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors.Enfuvirtide antiretroviral therapy in HIV-1 infection.The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype.Patterns of genomic site inheritance in HIV-1M inter-subtype recombinants delineate the most likely genomic sites of subtype-specific adaptation.
P2860
Q28469223-D128E856-0679-44B1-A699-736C408ABCD3Q28478943-D3779CE9-B325-4C25-92DD-72A86C2AA4FDQ30376865-172860BA-2B3E-490C-B288-702C2157FDC3Q30394295-9B5BA098-F62F-4F62-ADBD-1A938A5ADA29Q33622229-A47053A4-9805-4F60-B16D-8A438B07F654Q36086642-2640AD1B-1B71-4D25-A36E-79EFA7582613Q36981758-A240FE8D-1168-472F-9CD0-032E1F0BD87DQ37099189-F22163C1-1BDC-4D3F-B783-913451ED15ACQ37115773-717354D4-A29B-4A05-B7CB-A4F3EDD0F34EQ37259699-37D8A279-7249-4353-AF9F-23671D220C84Q37469938-1837AA35-F629-4E7C-8C81-9690EDA2E4D5Q37803237-69DD1D1D-7EA8-4D2E-8B0A-B750BDC7CCE1Q37945205-053EE2E3-FF3B-4C30-B61C-E6B722429523Q38076139-10FE2D39-CEA7-4B98-B076-3F6ED848B055Q38079744-7F21F65D-4D28-4069-AAD8-B2524C01AAA2Q38411845-3E52C4D5-F23A-400F-978C-95BF8FF5F1E2Q38423190-0632777C-2F2A-4BE3-8943-767863219D4FQ39619248-15ADBE30-33B6-4B31-AEDA-6F4141CBB69CQ39843204-4660D0C5-A518-4970-A2E3-7B46E8CAE91BQ39893554-42F2AC0D-D881-4BF2-BF74-0031FB544B1CQ40179461-B456FFAE-1F4E-4749-BEBB-825614048D30Q41715047-246EC669-E994-4E24-82B8-8C80FF7CCFB8Q42066659-212381A4-1D00-40CA-9AA9-8EA8CF2E5E4CQ55363352-D6AEE133-98D9-4EA2-82C3-36A9C07E4EB1
P2860
Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Role of the envelope genetic c ...... virus type 1-infected patients
@ast
Role of the envelope genetic c ...... virus type 1-infected patients
@en
type
label
Role of the envelope genetic c ...... virus type 1-infected patients
@ast
Role of the envelope genetic c ...... virus type 1-infected patients
@en
prefLabel
Role of the envelope genetic c ...... virus type 1-infected patients
@ast
Role of the envelope genetic c ...... virus type 1-infected patients
@en
P2093
P2860
P356
P1433
P1476
Role of the envelope genetic c ...... virus type 1-infected patients
@en
P2093
Armelle Goubard
Béatrice Labrosse
Fabrizio Mammano
Jean-Louis Labernardière
Jean-Luc Meynard
Jerôme Pacanowski
Laurence Morand-Joubert
Séverine Rochas
P2860
P304
P356
10.1128/JVI.02706-05
P407
P577
2006-09-01T00:00:00Z